시장보고서

상품코드

1575000

임상시험용 의약품 CDMO 시장 : 서비스 유형별, 약물 유형별, 단계별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Investigational New Drug CDMO Market, By Service Type, By Drug Type, By Phase, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 301 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

임상시험용 의약품 CDMO 시장 규모는 2023년 48억 9,032만 달러로 2024년부터 2032년까지 CAGR 6.90%로 확대될 것으로 예상됩니다.

임상시험용 의약품 CDMO 시장 - 시장 역학

임상시험 수 증가로 임상시험용 의약품 CDMO 시장 성장 가속화

임상시험 수가 증가하면서 임상시험용 의약품 CDMO 시장의 성장이 가속화되고 있습니다. 세계보건기구(WHO)에 따르면 2022년에는 전 세계적으로 4만 건 이상의 임상시험이 등록될 것으로 예상되며, 이는 연구 활동의 급격한 증가를 반영합니다. 미국 FDA도 IND 신청이 꾸준히 증가해 지난해 5,000건에 육박하는 것으로 보고했습니다. 이러한 증가의 배경에는 생명공학의 발전과 특히 종양학 및 희귀 질환과 같은 분야에서 새로운 치료법의 필요성이 대두되고 있기 때문입니다. Catalent와 Thermo Fisher Scientific과 같은 주요 기업들은 이러한 수요 증가에 대응하기 위해 시설과 용량을 확장하고 의약품 개발 및 제조를 위한 맞춤형 솔루션을 제공하고 있습니다. 또한, FDA의 Real-Time Oncology Review 프로그램과 같은 이니셔티브는 임상시험 프로세스를 가속화하는 것을 목표로 하고 있어 효율적인 CDMO 서비스의 필요성이 더욱 커지고 있습니다. 제약사들이 시장 개척 파이프라인을 간소화하기 위해 CDMO와의 제휴를 모색하는 추세가 강화됨에 따라 시장은 지속적으로 확대될 것으로 예상됩니다.

임상시험용 의약품 CDMO 시장 - 주요 인사이트

리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 매년 약 6.90%의 CAGR로 성장할 것으로 예상됩니다.

서비스 유형별로는 의약품 제조가 2023년 가장 큰 시장 점유율을 차지할 것으로 예측됐습니다.

약물 유형별로는 생물학적 제제가 2023년 주요 유형으로 꼽혔습니다.

단계별로는 2023년 2단계가 주요 유형으로 나타났습니다.

지역별로는 북미가 2023년 주요 수익원이었습니다.

임상시험용 의약품 CDMO 시장 - 세분화 분석:

세계 임상시험용 의약품 CDMO 시장은 서비스 유형, 약물 유형, 단계, 최종사용자 및 지역을 기준으로 세분화됩니다.

시장은 서비스 유형에 따라 원료의약품 제조, 의약품 제조, 포장 및 라벨링, 임상시험용 의약품 공급 등 4가지 범주로 나뉩니다. 의약품 제조는 임상시험용 최종 제제 개발에서 중요한 역할을 하기 때문에 시장을 주도하고 있습니다. 이어 원료의약품 제조가 근소한 차이로 2위, 임상시험용 의약품 공급이 3위, 포장 및 라벨링이 4위를 차지하고 있습니다.

시장은 약물 유형에 따라 저분자 의약품과 생물학적 제제의 두 가지 범주로 나뉩니다. 생물학적 제제는 수요 증가와 제조 공정의 복잡성으로 인해 우선순위를 차지하고 있습니다. 저분자 의약품은 여전히 시장의 대부분을 차지하고 있으며, 특히 전통 의약품과 제네릭 의약품에서 여전히 큰 비중을 차지하고 있습니다.

임상시험용 의약품 CDMO 시장 - 지리적 인사이트

임상시험용 의약품(IND) CDMO 시장은 지역별로 매우 다양하며, 특히 미국의 탄탄한 제약 환경으로 인해 북미가 주도하고 있으며, FDA는 2022년에 5,000건 이상의 IND 신청이 있을 것으로 예상하고 있어 이 지역의 활발한 임상시험 환경을 강조하고 있습니다. Catalent와 같은 주요 CDMO 업체들은 증가하는 수요에 대응하기 위해 이 지역에 대규모 시설을 설립하고 있습니다. 유럽 역시 독일, 영국 등 여러 국가들이 바이오의약품 연구에 많은 투자를 하고 있습니다. 유럽의약품청은 임상시험 승인을 간소화하기 위한 여러 이니셔티브를 지원하고 있으며, 이는 CDMO의 제휴를 더욱 촉진하고 있습니다. 아시아태평양에서는 임상시험 수 증가와 양호한 규제 환경에 힘입어 중국, 인도와 같은 국가들이 주요 기업으로 부상하고 있습니다. 중국에서만 2022년 임상시험 등록 건수가 35% 증가할 것으로 예상됩니다. 인도 정부도 임상 연구 역량을 강화하기 위한 이니셔티브를 시작하여 해외 투자를 유치하고 CDMO의 존재감을 높이고 있습니다. 이러한 다양한 지역적 상황은 임상시험용 의약품 CDMO 시장의 세계 성장 잠재력을 뒷받침하고 있습니다.

임상시험용 의약품 CDMO 시장 - 경쟁 상황:

임상시험용 의약품(IND) CDMO 시장의 경쟁 환경은 다양한 지역이 적극적으로 참여하고 있는 것이 특징입니다. 북미는 Thermo Fisher Scientific, Catalent 등 IND 프로젝트 처리 분야에서 높은 기술력과 풍부한 경험을 보유한 주요 업체들의 본거지이며, FDA가 보고한 IND 신청 건수의 증가는 2022년 5,000건 이상에 달할 것으로 예상되는 수요를 뒷받침하고 있습니다. 이러한 서비스에 대한 수요를 뒷받침하고 있습니다. 유럽도 강력한 경쟁자이며, Lonza와 Recipharm과 같은 기업들은 성장 시장의 요구를 충족시키기 위해 사업을 확장하고 있습니다. 독일의 강력한 규제 프레임워크와 영국의 임상시험 규제는 투자를 유치하는 데 있어 매우 중요합니다. 아시아태평양에서는 중국과 인도에서 바이오의약품 허브가 부상하고 있으며, 임상시험 효율화를 위한 정부 이니셔티브에 힘입어 우시 앱텍(WuXi AppTec)과 같은 기업이 주요 업체로 부상하고 있습니다. 중국에서는 2022년까지 임상시험 등록 건수가 35% 증가할 것으로 보고되고 있으며, 이는 빠르게 발전하는 이 시장의 경쟁 역학을 더욱 부각시키고 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 임상시험용 의약품 CDMO 업계

경쟁 대시보드
기업 개요
- Almac Group Limited
- Baxter BioPharma Solutions
- Boehringer Ingelheim International GmbH
- Cambrex Corporation
- Catalent, Inc.
- Charles River Laboratories International, Inc.
- CordenPharma International GmbH
- Fujifilm Diosynth Biotechnologies USA, Inc.
- Jubilant Life Sciences Limited
- Lonza Group AG
- Patheon Inc.(Thermo Fisher Scientific)
- Piramal Pharma Solutions
- Recipharm AB
- Samsung Biologics Co., Ltd.
- Siegfried Holding AG
- WuXi AppTec Co., Ltd.
- 기타

제13장 애널리스트의 전방위 전망

ksm 24.11.15

REPORT HIGHLIGHT

Investigational New Drug CDMO Market size was valued at USD 4,890.32 Million in 2023, expanding at a CAGR of 6.90% from 2024 to 2032.

The Investigational New Drug (IND) Contract Development and Manufacturing Organization (CDMO) Market focuses on services that support pharmaceutical companies in developing and manufacturing new drug candidates for clinical trials. The increasing number of clinical trials and the demand for specialized manufacturing services are significant factors propelling market growth. Furthermore, the rising investment in biopharmaceutical research and development, with over $200 billion allocated globally in 2022, underscores the need for efficient CDMO partnerships. However, stringent regulatory requirements and the high cost of compliance can restrain market entry for new players. Opportunities are emerging in the biotechnology sector, where the demand for tailored manufacturing solutions is rising; for example, companies like Lonza and WuXi AppTec are expanding their capabilities to cater to the growing biologics market. Additionally, the shift towards personalized medicine is creating a need for more flexible and scalable manufacturing solutions, enhancing the overall potential for CDMOs in the IND space.

Investigational New Drug CDMO Market- Market Dynamics

Increasing Number of Clinical Trials Accelerates Growth of the Investigational New Drug CDMO Market

The increasing number of clinical trials is significantly accelerating the growth of the Investigational New Drug (IND) CDMO Market. According to the World Health Organization, over 40,000 clinical trials were registered globally in 2022, reflecting a surge in research activity. The U.S. FDA has also reported a steady rise in IND applications, reaching nearly 5,000 submissions in the last year. This uptick is driven by advancements in biotechnology and the urgency for new therapies, particularly in areas like oncology and rare diseases. Major players like Catalent and Thermo Fisher Scientific are expanding their facilities and capabilities to meet this rising demand, offering tailored solutions for drug development and manufacturing. Additionally, initiatives such as the FDA's Real-Time Oncology Review program aim to expedite the clinical trial process, further propelling the need for efficient CDMO services. As pharmaceutical companies increasingly seek partnerships with CDMOs to streamline their development pipelines, the market is poised for continued expansion.

Investigational New Drug CDMO Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.90% over the forecast period (2024-2032)

Based on Service Type segmentation, Drug Product Manufacturing was predicted to show maximum market share in the year 2023

Based on Drug Type segmentation, Biologics was the leading type in 2023

Based on Phase segmentation, Phase II was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Investigational New Drug CDMO Market- Segmentation Analysis:

The Global Investigational New Drug CDMO Market is segmented on the basis of Service Type, Drug Type, Phase, End-User, and Region.

The market is divided into four categories based on Service Type: Drug Substance Manufacturing, Drug Product Manufacturing, Packaging & Labeling, and Clinical Trial Supply. Drug Product Manufacturing leads due to its critical role in developing final formulations for clinical trials. Drug Substance Manufacturing follows closely, while Clinical Trial Supply and Packaging & Labeling rank third and fourth, respectively.

The market is divided into two categories based on Drug Type: Small Molecules and Biologics. Biologics take precedence due to their increasing demand and complexity in manufacturing processes. Small Molecules follow, still representing a significant portion of the market, particularly for traditional pharmaceuticals and generic drugs.

Investigational New Drug CDMO Market- Geographical Insights

The Investigational New Drug (IND) CDMO Market exhibits significant geographical diversity, with North America leading, particularly due to the United States' robust pharmaceutical landscape. The FDA reported over 5,000 IND applications in 2022, highlighting the region's active clinical trial environment. Major CDMO players like Lonza and Catalent have established extensive facilities in this region to cater to growing demand. Europe follows closely, with countries like Germany and the UK investing heavily in biopharmaceutical research; the European Medicines Agency supports numerous initiatives to streamline clinical trial approvals, further encouraging CDMO partnerships. In the Asia-Pacific region, countries like China and India are emerging as key players, driven by an increasing number of clinical trials and favorable regulatory environments; China alone saw a 35% rise in clinical trial registrations in 2022. The Indian government has also launched initiatives to enhance its clinical research capabilities, attracting foreign investments and strengthening its CDMO presence. This diverse regional landscape underscores the global potential for growth in the IND CDMO market.

Investigational New Drug CDMO Market- Competitive Landscape:

The Competitive Landscape of the Investigational New Drug (IND) CDMO Market is marked by active engagement across various regions. North America stands out as the leading region, home to major players like Thermo Fisher Scientific and Catalent, which leverage advanced technologies and extensive experience in handling IND projects. The FDA's reported increase in IND applications, exceeding 5,000 in 2022, underscores the demand for these services. Europe is also a strong contender, with companies like Lonza and Recipharm expanding their operations to meet the needs of a growing market; Germany's robust regulatory framework and the UK's Clinical Trial Regulations are pivotal in attracting investments. In the Asia-Pacific region, the rise of biopharmaceutical hubs in China and India is notable, with firms like WuXi AppTec emerging as key players, supported by governmental initiatives aimed at enhancing clinical trial efficiency. China's reported 35% increase in clinical trial registrations in 2022 further highlights the competitive dynamics in this fast-evolving market.

Recent Developments:

In October 2023, Evaluate launched its CDMO Intelligence solution, providing comprehensive market insights for contract development and manufacturing organizations (CDMOs) and biopharma firms. This tool aims to optimize strategies in the rapidly growing pharmaceutical CDMO market, projected to expand significantly through 2028.

In October 2023, Tanvex BioPharma launched Tanvex CDMO, providing comprehensive contract development and manufacturing services for biologics. Located in San Diego, it features advanced facilities and aims to assist biopharmaceutical companies in advancing products from investigational new drug (IND) status to market readiness.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Almac Group Limited
Baxter BioPharma Solutions
Boehringer Ingelheim International GmbH
Cambrex Corporation
Catalent, Inc.
Charles River Laboratories International, Inc.
CordenPharma International GmbH
Fujifilm Diosynth Biotechnologies USA, Inc.
Jubilant Life Sciences Limited
Lonza Group AG
Patheon Inc. (Thermo Fisher Scientific)
Piramal Pharma Solutions
Recipharm AB
Samsung Biologics Co., Ltd.
Siegfried Holding AG
WuXi AppTec Co., Ltd.
Others

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

Drug Substance Manufacturing
Drug Product Manufacturing
Packaging & Labeling
Clinical Trial Supply

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Small Molecules
Biologics

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY PHASE- MARKET ANALYSIS, 2019 - 2032

Phase I
Phase II
Phase III

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Pharmaceutical Companies
Biopharmaceutical Companies
Biotechnology Firms

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Investigational New Drug CDMO Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Investigational New Drug CDMO Market Snippet by Service Type
- 2.1.2. Investigational New Drug CDMO Market Snippet by Drug Type
- 2.1.3. Investigational New Drug CDMO Market Snippet by Phase
- 2.1.4. Investigational New Drug CDMO Market Snippet by End-User
- 2.1.5. Investigational New Drug CDMO Market Snippet by Country
- 2.1.6. Investigational New Drug CDMO Market Snippet by Region
2.2. Competitive Insights

3. Investigational New Drug CDMO Key Market Trends

3.1. Investigational New Drug CDMO Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Investigational New Drug CDMO Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Investigational New Drug CDMO Market Opportunities
3.4. Investigational New Drug CDMO Market Future Trends

4. Investigational New Drug CDMO Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Investigational New Drug CDMO Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Investigational New Drug CDMO Market Landscape

6.1. Investigational New Drug CDMO Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Investigational New Drug CDMO Market - By Service Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Service Type, 2023 & 2032 (%)
- 7.1.2. Drug Substance Manufacturing
- 7.1.3. Drug Product Manufacturing
- 7.1.4. Packaging & Labeling
- 7.1.5. Clinical Trial Supply

8. Investigational New Drug CDMO Market - By Drug Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
- 8.1.2. Small Molecules
- 8.1.3. Biologics

9. Investigational New Drug CDMO Market - By Phase

9.1. Overview
- 9.1.1. Segment Share Analysis, By Phase, 2023 & 2032 (%)
- 9.1.2. Phase I
- 9.1.3. Phase II
- 9.1.4. Phase III

10. Investigational New Drug CDMO Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Pharmaceutical Companies
- 10.1.3. Biopharmaceutical Companies
- 10.1.4. Biotechnology Firms

11. Investigational New Drug CDMO Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Investigational New Drug CDMO Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Investigational New Drug CDMO Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Investigational New Drug CDMO Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Investigational New Drug CDMO Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Investigational New Drug CDMO Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Investigational New Drug CDMO Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Almac Group Limited
- 12.2.2. Baxter BioPharma Solutions
- 12.2.3. Boehringer Ingelheim International GmbH
- 12.2.4. Cambrex Corporation
- 12.2.5. Catalent, Inc.
- 12.2.6. Charles River Laboratories International, Inc.
- 12.2.7. CordenPharma International GmbH
- 12.2.8. Fujifilm Diosynth Biotechnologies USA, Inc.
- 12.2.9. Jubilant Life Sciences Limited
- 12.2.10. Lonza Group AG
- 12.2.11. Patheon Inc. (Thermo Fisher Scientific)
- 12.2.12. Piramal Pharma Solutions
- 12.2.13. Recipharm AB
- 12.2.14. Samsung Biologics Co., Ltd.
- 12.2.15. Siegfried Holding AG
- 12.2.16. WuXi AppTec Co., Ltd.
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us